Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom
Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.
How this was made
The 30-second read
Why it matters
The announced revenue reductions could depress earnings forecasts for major lab providers.
Market read
The news directly affects Labcorp (LH) and Quest Diagnostics (DGX) and may influence the broader lab services sector.
What to watch
Potential for legislative amendments before finalization could mitigate the impact.
Background
CMS is set to lower payments on 775 lab tests by 15% starting Jan 1 2027, prompting industry lobbying.
Ticker impact
Labcorp said its 2027 revenue will be hit by $125 million due to the CMS payment cuts.
downward pressure as investors price in the $125 M hit
The disclosed $125 M revenue impact is material for a large cap and is a new primary quote.
Quest Diagnostics estimated the payment cuts will shave roughly 1% off its 2026 revenue.
slight downside as the market incorporates the 1% revenue hit
First report of Quest's quantified impact makes the news actionable for the stock.
Market effects
Clinical laboratory sector may see compressed margins across peers.
U.S. healthcare services stocks could face valuation pressure.
Limited to U.S. labs; no immediate global ripple.
Counterpoint
If the cuts spur consolidation, larger labs could gain market share despite short-term hits.
Key entities
- RegulatorCenters for Medicare & Medicaid Services
Issuer of the preliminary fee schedule.
- Industry GroupAmerican Clinical Laboratory Association
Provides data on the upcoming payment cuts.
